Association of BIM deletion polymorphism with intrinsic resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma

This study explores the impact of BIM polymorphism on treatment outcome of patients with advanced adenocarcinoma, comparing those who experienced primary resistance with those who had partial response after treatment with epidermal growth factor receptor tyrosine kinase inhibitors.